Fushen Sha MD

PubMed

• 2 citations
  Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
  Fushen Sha, Michelle Okwali, Anna Alperovich, Philip C Caron, Lorenzo Falchi
  Blood Cancer Journal. 2022-02-10
• 19 citations
  Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors.
  Zhiyang Li, Xin Wu, Yanjie Zhao, Yinan Xiao, Yunuo Zhao
  Medcomm. 2021-03-01
• Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.
  Yinan Xiao, Hanyue Xu, Wen Guo, Yunuo Zhao, Yuling Luo
  Molecular Biomedicine. 2020-12-03

Journal Articles

• Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse  
  Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, Palomba MLM, Portlock C, Straus DJ, Noy A, Horwitz SM, Moskowitz A, Hamlin P, Moskowitz CH, Matasar MJ, Zelenetz AD..., Blood Cancer J, 5/20/2019
• Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma  
  Kumar A, Ying Z, Alperovich A, Dogan A, Hamlin P, Moskowitz C, Pichardo J, Portlock C, Sha F, Zelenetz AD, Zhang Z, Drill E, Woo K, Younes A, Haematologica, 4/2019
• miR-183 potentially inhibits NF-κB1 expression by directly targeting its 3'-untranslated region  
  Sha F, Wu S, Zhang H, Guo X, Acta Biochim Biophys Sin, 10/1/2014

Books/Book Chapters

• Chinese Guidelines on the Diagnosis and Treatment of Lymphoma 
  Chapter: Diagnosis and Treatment of Hodgkin's Lymphoma 
  Page 110 - 120Ma J, Shuang Y, Wu G, Zhu J, Zhu H, Li Z, Qiu L, Shen L, Su L, Chen J, Zhou J, Yi P, Lin T, Lin S, Jin J, Xu B, Gu K, Gao Z, Huang H, Bao H, Wang Z, Fang X, Sha F*, Re...Editors: In Ye Y, Wang M, Long H.China Medical TribuneEdition 2017,2017

Abstracts/Posters

• Impact of PET Imaging and Histological Transformation on the Prognosis of Early Disease Progression in Follicular Lymphoma
  Batlevi CL, Sha F*, Alperovich A, Ni A, Smith K, Ying Z, Gerecitano J, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz G, Noy A, Palomba M, Portlock C,..., International Conference on Malignant Lymphoma (ICML), Lugano, CHE, 6/2019
• Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II...
  Lin T, Sha F, Huang H, Wang Z, Lin S, Li X, Hong X, Fang X, Li F,Peng C, Ren Q, Zhang L, Liu Q, American Society of Clinical Oncology, Chicago, IL, 6/2018
• Randomized, open-label, phase II trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lym...
  Huang H, Li X, Hong H, Wang Z, Fang X, Li F, Peng C, Ren Q, Sha F*, Zhang L, Lin S, Liu Q, Lin T, American Society of Clinical Oncology, Chicago,IL, 1949